Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cancer registry tracks thousands to map disease course

NCT ID NCT06956755

Knowledge-focused Sponsor: Groupe Francophone des Myelodysplasies Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are building a registry to collect long-term health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia. The study gathers details on blood counts, bone marrow tests, genetic changes, and treatments. By following these patients over time, the registry aims to understand how the diseases progress and how different care approaches affect outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry succeeds, it could give doctors a clearer picture of how myelodysplastic syndromes and therapy-related acute myeloid leukemia progress and how different treatments affect survival.
What could go wrong
This is an observational registry, so it cannot prove that any treatment works. The data may be incomplete or reflect only the patients who join, which limits how well the findings apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 6,990 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2003

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Included in the "Registry" are all patients over 18 years of age with myelodysplastic syndrome and therapy-related acute myeloid leukemia

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female * Age \> 18 years * Patients with myelodysplastic syndrome and therapy-related acute myeloid leukemia * Able and willing to provide written informed consent Exclusion Criteria: * Age \<18 years * Patient is unwilling or unable to give consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Leukemia, myeloid, acute are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Leukemia, myeloid, acute Myelodysplastic syndromes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aspasia Stamatoullas

    RECRUITING

    Rouen, 76038, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.